Structure-function analysis of the glucose-6-phosphate transporter deficient in glycogen storage disease type Ib

被引:44
作者
Chen, LY [1 ]
Pan, CJ [1 ]
Chou, JY [1 ]
机构
[1] NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1093/hmg/11.25.3199
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glycogen storage disease type Ib (GSD-Ib) is caused by a deficiency in the glucose-6-phosphate transporter (G6PT), a 10 transmembrane domain endoplasmic reticulum protein. To date, 69 G6PT mutations, including 28 missenses and 2 codon deletions, have been identified in GSD-Ib patients. We previously characterized 15 of the missense and one codon deletion mutations using a pSVL-based expression assay. A lack of sensitivity in this assay limited the discrimination between mutations that lead to loss of function and mutations that leave a low residual activity. We now report an improved G6PT assay, based on an adenoviral vector-mediated expression system and its use in the functional characterization of all 30 codon mutations found in GSD-Ib patients. Twenty of the naturally occurring mutations completely abolish microsomal G6P uptake activity while the other 10 mutations, including 5 previously characterized ones, partially inactivate the transporter. This information should greatly facilitate genotype-phenotype correlation. We also report a structure-function analysis of G6PT. In addition to the 3 destabilizing mutations reported previously, we now show that the G50R, C176R, V235del, G339C and G339D mutations also compromise the G6PT stability. Mutation analysis of the amino-terminal domain of G6PT shows that it is required for optimal G6P uptake activity. Finally, we show that degradation of both wild-type and mutant G6PT is inhibited by a potent proteasome inhibitor, lactacystin, demonstrating that G6PT is a substrate for proteasome-mediated degradation.
引用
收藏
页码:3199 / 3207
页数:9
相关论文
共 31 条
[1]   The gene for glycogen-storage disease type 1b maps to chromosome 11q23 [J].
Annabi, B ;
Hiraiwa, H ;
Mansfield, BC ;
Lei, KJ ;
Ubagai, T ;
Polymeropoulos, MH ;
Moses, SW ;
Parvari, R ;
Hershkovitz, E ;
Mandel, H ;
Fryman, M ;
Chou, JY .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (02) :400-405
[2]   Metabolic engineering with recombinant adenoviruses [J].
Antinozzi, PA ;
Berman, HK ;
O'Doherty, RM ;
Newgard, CB .
ANNUAL REVIEW OF NUTRITION, 1999, 19 :511-544
[3]   NEUTROPENIA AND IMPAIRED NEUTROPHIL MIGRATION IN TYPE-IB GLYCOGEN-STORAGE DISEASE [J].
BEAUDET, AL ;
ANDERSON, DC ;
MICHELS, VV ;
ARION, WJ ;
LANGE, AJ .
JOURNAL OF PEDIATRICS, 1980, 97 (06) :906-910
[4]   ER-associated and proteasome-mediated protein degradation: How two topologically restricted events came together [J].
Brodsky, JL ;
McCracken, AA .
TRENDS IN CELL BIOLOGY, 1997, 7 (04) :151-156
[5]  
Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO
[6]  
2-J
[7]  
Cheng J, 2000, WORLD J GASTROENTERO, V6, P275
[8]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[9]  
Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798
[10]  
Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104